CJC-1295 vs Tesamorelin

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicCJC-1295Tesamorelin
What it is

A synthetic analogue of growth hormone-releasing hormone, 29 amino acids long. A version with an added drug affinity complex (DAC) binds to albumin in the blood and lasts longer.4

A growth hormone-releasing factor (GHRF) analogue. The label states that it binds to and stimulates human GRF receptors with potency similar to the natural hormone.2

FDA status

Not FDA-approved

Unapproved new drug in cited enforcement record1

Not FDA-approved. FDA staff recommended in 2024 against adding any CJC-1295-related substance to the 503A compounding list, and FDA lists CJC-1295 among compounding substances that may present significant safety risks.4,5

Is CJC-1295 FDA-approved?

FDA-approved

FDA-approved as Egrifta for HIV-associated abdominal fat2,3

FDA-approved. Drugs@FDA lists Egrifta (first approved November 10, 2010), and the label covers reducing excess abdominal fat in adults with HIV and lipodystrophy. The cited label has no boxed warning.2,3

Is tesamorelin FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.6

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. CJC-1295 is not among them.6,7

Not among the six peptides the policy lists.6

FDA compounding safety-risk page

Listed.

FDA’s compounding safety-risk page, current as of April 22, 2026, lists CJC-1295 among substances whose nominations were withdrawn, citing possible immune reactions, impurities and serious adverse events including increased heart rate.5

Not addressed in this profile’s sources.

Kinds of studies cited

Smaller controlled human trials

  • Controlled human trial Two placebo-controlled studies in healthy adults published in 2006, in which most participants received one or a few exposures to a CJC-1295 DAC substance and growth hormone and IGF-1 levels were measured.4
  • Small, short, or incompletely reported human study FDA counted 63 healthy adults, 87% of them men, exposed to a CJC-1295 DAC substance across three published studies; 73% received a single exposure.4
  • Animal or laboratory research Animal studies in which a CJC-1295 DAC substance acted as a growth hormone secretagogue, and toxicology studies in rats and dogs that showed bleeding, inflammation and tissue death where it was given.4

Large randomized human trials

  • Large randomized human trial Study 1 (NCT00123253): a randomized, double-blind, placebo-controlled trial in 412 adults with HIV, lipodystrophy and excess abdominal fat, with visceral fat measured by CT scan at 26 weeks.2
  • Large randomized human trial Study 2 (NCT00435136): a randomized, double-blind, placebo-controlled trial of the same design in 404 adults.2
Records collected

0 ClinicalTrials.gov records and 9 PubMed records collected

11 ClinicalTrials.gov records and 21 PubMed records collected

Area of study

Hormones4

Metabolic and weight2

Latest dated events
  1. FDA’s compounding safety-risk page, as last updated, lists CJC-1295 among withdrawn nominations with safety concerns.5
  2. FDA’s Pharmacy Compounding Advisory Committee meets to discuss CJC-1295-related substances.4,8
  3. FDA staff date their evaluation recommending against adding CJC-1295-related substances to the 503A bulks list.4
  1. DailyMed publishes the Egrifta SV label version cited on this page.2
  2. FDA approves Egrifta, according to Drugs@FDA.3

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Nicholasville Compounding Pharmacy and Its Owner Plead Guilty to Unlawful Distribution of Prescription Drugs ↗

    U.S. Department of Justice · Official source · Source checked July 22, 2026

  2. 2
    EGRIFTA SV (tesamorelin) kit · SPL version 9 · published 2026-07-31 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026

  3. 3
    Drugs@FDA application BLA022505 · original submission status AP · 2010-11-10 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  4. 4
    FDA evaluation of five CJC-1295-related bulk substances, November 15, 2024 ↗

    U.S. Food and Drug Administration · Official source · Source checked September 15, 2026

  5. 5
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  6. 6
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  7. 7
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  8. 8
    Federal Register notice 2024-24828 · published 2024-10-25 · Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List ↗

    Federal Register via GovInfo · Official source · Source checked August 21, 2026